73 results about "Serum amyloid protein" patented technology

The invention discloses a kit for detecting the content of a serum amyloid protein A. The kit comprises a reagent R1, a reagent R2 and a serum amyloid protein A calibrator, wherein the reagent R1 comprises a first buffer solution, a first electrolyte, a surfactant, a first stabilizer, a high-molecular accelerant and a first preservative; the reagent R2 comprises a second buffer solution, anti-human serum amyloid protein A antibody coated latex particles, a second electrolyte, a second stabilizer and a second preservative; the serum amyloid protein A calibrator comprises a third buffer solution, a third stabilizer, a third preservative, an antioxidant and an anti-human serum amyloid protein A antigen. The invention further discloses an application of the kit for detecting the content of the serum amyloid protein A to the detection of the content of the serum amyloid protein A and a method for detecting the content of the serum amyloid protein A by adopting the kit for detecting the content of the serum amyloid protein A. By adopting the kit and the method disclosed by the invention, the content of the serum amyloid protein A can be detected easily and rapidly.

The invention relates to a fluorescence immunochromatographic method of serum amyloid protein A and a detection kit thereof. The method includes the steps of preparing a probe fixing pad, preparing an immunochromatographic test strip, preparing a sample diluting liquid and detecting a sample. The probe fixing pad is prepared by mixing serum amyloid protein A monoclonal antibody fluorescent latex particles and goat-anti-rabbit IgG fluorescent latex particles, and diluting the mixture with a gold diluent and spraying the liquid onto glass fibers. A detection line is coated with serum amyloid protein A monoclonal antibody and a control line is coated with goat-anti-rabbit IgG to prepare the immune-chromatographic test strip. The detection kit includes an immune-chromatographic detection card including a PVC lining plate, a sample pad, the probe fixing pad, a nitrocellulose membrane and a water absorbing paper. The probe fixing pad is prepared by mixing and drying the serum amyloid protein A monoclonal antibody fluorescent latex particles and the goat-anti-rabbit IgG fluorescent latex particles, so that the detection kit is high in detection sensitivity and accuracy, is simple in operation and is low in cost.

The invention discloses a serum amyloid protein A detection method. The serum amyloid protein A detection method comprises following steps: serum SAA antigen of a tested body is mixed with a latex cross-linked substance coated with SAA antibody, in vitro agglutination reaction is carried out, and quantitative determination of the content of SAA in serum is carried out. The invention also discloses a serum amyloid protein A detection reagent. The serum amyloid protein A detection method and the reagent possesses following advantages: linearity range is wide, detection is rapid, detection sensitivity is high, accuracy is high, cost is low, and the reagent is stable.

The embodiment of the invention relates to the field of immunodetection, in particular to a human serum amyloid protein A determination kit with high sensitivity and a wide detection range. The humanserum amyloid protein A determination kit comprises a reagent 1, a reagent 2 and SAA calibrators with different concentration gradients, wherein the reagent 2 comprises carboxylated latex microspheresonly labeled with human SAA monoclonal antibodies and carboxylated latex microspheres only labeled with human SAA polyclonal antibodies; the average particle size of the carboxylated latex microspheres only labeled with the human SAA monoclonal antibodies is larger than the average particle size of the carboxylated latex microspheres only labeled with the human SAA polyclonal antibodies. The kitcan be used for detecting a single sample within 10 minutes; the kit has the advantages that the kit is simple in structure and excellent in precision, accuracy, linearity, interference resistance andother indexes, can well diagnose early inflammation of infectious diseases, can detect the content of SAA in serum and the content of SAA in blood plasma, is very suitable for clinical biochemical analyzers, and greatly facilitates clinical examination.

The invention relates to a test paper strip for (PCT/SAA) combined rapid detection of human procalcitonin/serum amyloid protein A. The test paper strip comprises a detecting card shell, a test strip, a sample pad, a gold conjugate pad coated with two colloidal gold labeled antibodies, a nitrocellulose membrane and water absorbing paper, wherein the nitrocellulose membrane is provided with a T1 detection line coated with a solid-phase matched anti-SAA monoclonal antibody, a T2 detection line coated with a solid-phase matched anti-PCT monoclonal antibody, and a control line C which is parallel to the detection line and coated with a goat anti mouse IgG monoclonal antibody. Two kinds of colloidal gold labeled antibodies are provided, which are respectively a colloidal gold labeled antibody which can be specifically combined with a to-be-detected antigen PCT and an antibody which can be specifically combined with a to-be-detected antigen SAA. The test paper strip disclosed by the invention can be used for simultaneously and rapidly detecting the PCT/SAA in a patient sample in a combined manner and has the advantages of improving the diagnosis accuracy of early inflammatory reaction of infectious diseases and being simple to operate, rapid and convenient.

The invention relates to a non-small cell lung cancer molecular marker and its application, specifically to an application of human leucine-rich alpha2 glycoprotein or its segment, human C4 binding protein or its segment, human serum amyloid protein or its segment, or the combination thereof in the preparation of a preparation for detecting whether an object has the non-small cell lung cancer or performing a prognosis treatment for those who suffer from the non-small cell lung cancer.

The invention discloses a serum amyloid protein A determination kit and a use method thereof. The serum amyloid protein A determination kit comprises first detection liquid and second detection liquid, wherein the first detection liquid includes first detection liquid Tris-HCl buffer liquid and first detection liquid sodium azide, and the second detection liquid includes second detection liquid Tris-HCl buffer liquid, second detection liquid sodium azide and latex particles coated with anti-human serum amyloid protein A antibodies. According to the serum amyloid protein A determination kit and the use method of the serum amyloid protein A determination kit, by adopting latex-enhanced immunoturbidimetry, the operation is simple, the accuracy is high, and the popularization is facilitated.

The invention discloses a reagent for quantitatively detecting serum amyloid proteins A in whole blood. The reagent comprises reagents R1 and reagents R2. The reagents R1 comprise disruption components, buffer solution, surfactants, electrolyte, preservatives, reaction promoters and stabilizers; the reagents R2 comprise latex particles, surfactants, electrolyte, preservatives, stabilizers and buffer solution; the disruption components are used for removing measurement interference red blood cells, blood cells are not separated by the disruption components, and the original whole blood can be used; anti-human SAA antibodies are coated by the latex particles, and the particle sizes of the latex particles are 50-300 nm. The reagent has the advantages that a detection sample can be the whole blood such as peripheral blood, requirements on high sensitivity and wide linear ranges can be simultaneously met, the reagent is excellent in anti-interference performance, accuracy and precision, and clinical examination requirements can be met. The invention further discloses a method for quantitatively detecting the serum amyloid proteins A in the whole blood.

The invention relates to a serum amyloid protein A/procalcitonin/C-reactive protein three-in-one determination kit. The determination kit is provided with a test paper card and is characterized in that a PVC plate, a sample pad, a binding pad, a nitrocellulose membrane and a water absorbing pad are sequentially arranged on the test paper card from bottom to top, wherein the binding pad is adsorbed with three monoclonal antibody-microsphere coupling compounds, namely antiserum amyloid protein A, antiprocalcitonin, anti-C-reactive protein which are labeled by rare earth Eu<3+> fluorescent microspheres respectively, the diameter of the rare earth fluorescent microspheres is 150nm, and the rare earth fluorescent microspheres contain rare earth lanthanide element Eu<3+>, are stable in a basic state and transmit fluorescent light with the wavelength of 615nm under the action of an excitation light source at 337nm; and the monoclonal antibodies are purified mixed monoclonal antibodies which are respectively from monoclonal antibody cell strains specific to 2-6 different antigen epitopes such as serum amyloid protein A, procalcitonin and C-reactive protein. The determination kit provided by the invention has the advantages of simple and convenient operation, quick response, high sensitivity, strong specificity and the like.

The invention relates to an application of a serum amyloid protein A1. A kit comprises siRNAs shown in SEQ ID NO:1-4 or a polyclonal antibody of the serum amyloid protein A1 of a sequence shown in SEQIDNO:5. The serum amyloid protein A1 as a target of lung cancer metastasis effectively inhibits SAA1 to promote invasion of lung cancer cells by interfering cell SAA1 through siRNA.

The invention discloses a two-in-one determination kit for serum amyloid protein A and C-reactive protein. A test strip is arranged on the determination kit, and the determination kit is characterized in that a PVC board, a sample pad, a combined pad, a nitrocellulose membrane and a water absorbent pad are sequentially arranged on the test strip from bottom to top, wherein two monoclonal antibody-micro-spherical coupling compounds of the anti-serum amyloid protein A and anti-C-reactive proteins which are respectively marked by rare earth Eu<3+> fluorescent microspheres are adsorbed on the combined pad; the diameter of the rare earth fluorescent microspheres is 150nm; the fluorescent microspheres contain rare earth lanthanide elements Eu<3+> and is stable in a basic state, and fluorescence with wavelength of 615nm can be emitted under an action of an excitation light source with the length of 337nm; the monoclonal antibodies are the purified and mixed monoclonal antibodies, which are respectively originated from monoclonal antibody cell strains for 2-6 different serum amyloid protein A and C-reactive protein antigenic epitopes. The two-in-one determination kit has the advantages of convenient operation, quick reaction, high sensitivity, strong specificity and the like.

A method of diagnosing tuberculosis (TB) disease and distinguishing between active TB and latent TB infection in a subject is described herein. A sample from the subject is stimulated with at least one Mycobacterium tuberculosis (M.tb) infection phase-dependent antigen selected from Rv0081, Rv2032, Rv1737c, Rv2389c, Rv0867c, TB18.2, Rv2099c, Rv1733c, M.tb PPD, PHA and ESAT-6/CFP-10 and the presence of at least one host marker in the sample is detected, the host marker being selected from EGF, TGF-α, TNF-α, VEGF, RANTES, IL-12(p40), IL-12(p70), IL-10, IP-10, IFN-α2, fractalkine, IFN-γ, IL-13, IL-1Ra, IL-3, IL-4, IL-5, MIP-1α, ENA-78, BCA-1, TARC, X6-Ckine, eotaxin, eotaxin-2, SCF, APOA-1, APOE, HPALBN, HCF, Serum amyloid protein A (SAA), C-reactive protein (CRP), serum amyloid protein P (SAP), TIMP-1, MIP-1β, IL-6, GM-CSF, IL-1α, MMP-9, MMP-2, MCP-1, TRAIL, IL-15, IL-17F, IL-22, TNF-β, MCP-2 and MCP-4. Additional host markers may also be detected in an unstimulated sample from the subject.

The invention relates to a serum amyloid protein A and procalcitonin two-in-one determination kit and a preparation method. The kit is provided with a test paper card, and the test paper card is characterized by being provided with a PVC plate, a sample pad, a combination pad, a nitrocellulose membrane and a water absorption pad from top to bottom in order. Specifically, rare earth Eu<3+> fluorescent microsphere respectivel labelled anti-serum amyloid protein A and anti-procalcitonin two monoclonal antibody-microsphere coupled compounds are adsorbed on the combination pad, the rare earth fluorescent microsphere has a diameter of 150nm, the rare earth fluorescent microsphere contains rare earth lanthanide Eu<3+>, is stable under a ground state, and can emit fluorescence with a wavelength of 615nm under the action of a 337nm excitation light source. The monoclonal antibodies are purified mixed monoclonal antibodies, and are respectively derived from monoclonal antibody cell lines directed at 2-6 different serum amyloid proteins A and procalcitonin epitopes. The kit has the advantages of simple operation, quick response, high sensitivity and strong specificity, etc.

The invention relates to the field of biotechnology, and provides a primer and a method for mass spectrometric detection of hotspot mutation of PIK3CA genes by using the primer. The method comprises the following steps of: (1) positioning hotspot mutation sites of the PIK3CA genes; (2) designing a primer for amplified reaction and a primer for extension reaction according to deoxyribonucleic acid (DNA) sequences at two ends of the mutation sites; (3) performing the amplified reaction; (4) performing treatment by using a serum amyloid protein (SAP) enzyme (alkaline phosphatase); (5) performing the extension reaction; (6) purifying a product of the extension reaction by using resin; (7) transferring the product purified by the resin to a chip; (8) putting the chip in a mass spectrograph, and running a detection procedure; and (9) reading and analyzing detection data, and determining the gene type of a target site of the PIK3CA genes. Compared with the conventional detection method, the method provided by the invention has the characteristics of high sensitivity, high accuracy, high flux and low cost.

The invention relates to a testing reagent for serum amyloid protein A and a preparation method of the testing reagent and belongs to the technical field of testing of biochemical means. The testing reagent comprises a reagent R1, a reagent R2 and a serum amyloid protein A standard substance, wherein main ingredients of the reagent R1 are trihydroxymethyl aminomethane and NaN3; main ingredients of the reagent R2 are latex granules enveloping antibodies resisting to human serum amyloid protein A as well as NaN3; main ingredients of the serum amyloid protein A standard substance are serum amyloid protein A, bovine serum albumin, a phophate buffer solution and NaN3. The testing reagent is used for testing serum amyloid protein A and has the advantages of fastness, sensitivity, good accuracy, good stability, simplicity and convenience in operation and the like.

The invention discloses a serum amyloid protein A mutant which has an amino acid sequence as shown in SEQ ID NO.1 and still has antigenicity of serum amyloid protein after several amino acids are replaced, so that a unique mutant is obtained. The SAA mutant is obtained by replacing four amino acids in natural SAA protein, so that the in-vitro stability of the SAA mutant is improved. Experiments prove that obtained SAA protein is soluble mature protein, the activity of the SAA protein is kept to the maximum extent, and the antigenicity of natural SAA protein is reserved. The invention also discloses application and a preparation method of the serum amyloid protein A mutant.

The invention relates to a serum amyloid protein A (SAA) measuring kit, and a measuring method thereof, and belongs to the technical field of medicine biological detection. The kit comprises a reagent (1), a reagent (2), a calibration material, and a quality control material. The reagent (1) comprises Tris-HCl, sodium azide, and PEG-6000. The reagent (2) comprises Tris-HCl, emulsion particles with an embedded anti-human serum amyloid protein A antibody, sodium azide, octyl phenol polyoxyethylene, and methyl paraben. The calibration material comprises a serum amyloid protein A antigen, and sodium azide. The quality control material comprises a serum amyloid protein A antigen, and sodium azide. The provided serum amyloid protein A (SAA) measuring kit and measuring method thereof have the advantages that compared with the latex immunological turbidimetry technology, the analysis sensitivity is high, the results are accurate, the operation is simple, and the cost is proper, and thus the method is convenient for popularization.

The invention provides a method for quantitatively detecting SAA/PCT/CRP (Serum Amyloid Protein A/Procalcitonin/C-Reactive Protein) simultaneously. Test paper of human SAA, test paper of PCT and test paper of CRP, which are mutually independent, a triple card shell and an immunochromatographic interpretation result recorder with a corresponding judgment method and a standard curve are used for quantitatively detecting SAA/PCT/CRP simultaneously and rapidly. The detection method is simple and stable and does not require a large number of samples, thereby reducing the medical cost; and the method has high sensitivity and can rapidly and quantitatively detect SAA/PCT/CRP simultaneously.

In part, the disclosure relates to methods of treating fibrotic cancers by administering one or more Serum Amyloid Protein (SAP) agonists. In certain aspects, the method further comprises the conjoint administration of an anti-cancer therapeutic, e.g., a chemotherapeutic agent. In certain aspects, the disclosure relates to methods of treating myelofibrosis by administering an SAP agonist and optionally one or more anti-cancer therapeutic agents.

The invention belongs to the technical field of bioengineering and relates to a recombinant protein. The recombinant protein contains two dominant epitopes of a cat serum amyloid protein A; and an amino acid sequence of the recombinant protein is converted into a corresponding nucleotide sequence by virtue of an escherichia coli preferred codon, the nucleotide sequence is chemically synthesized, and a recombinant expression vector is constructed, so that the yield of the recombinant protein in a prokaryotic expression system is increased. The invention further relates to preparation of the monoclonal antibody of the recombinant protein. A hybridoma cell strain is obtained through immunization, cell fusion and repeated screening, the monoclonal antibody is purified, europium ions (Eu3<+>) are respectively marked, and an optimal monoclonal antibody pairing combination is determined through an orthogonal experiment and can be applied to the early diagnosis of cat infectious inflammations.

The invention relates to a latex immunoturbidimetry detection kit for quantitatively determining cat serum amyloid protein A. The latex immunoturbidimetry detection kit comprises reagent beads formedby freeze-drying polystyrene latex particles sensitized by a cat serum amyloid protein A antibody, a reagent disc for detection, water cup water for diluting a sample, a cat serum amyloid protein A calibration product and a quality control product. The product can accurately and quantitatively detect the content of the cat serum amyloid protein A, can monitor the early inflammation of infectious diseases according to the content of the cat serum amyloid protein A, is beneficial to diagnosing inflammation, evaluating the activity of the cat serum amyloid protein A and monitoring the activity and treatment of the cat serum amyloid protein A, and has very high clinical value. The kit has the advantages of high specificity, high sensitivity, high precision, high accuracy, simplicity, convenience, quickness and the like.

The embodiment of the invention relates to the technical field of chemical analysis, and particularly relates to a kit and a detection system. The kit comprises a shell, a reagent, a magnetic card anda stirrer. The reagent comprises an antiserum, a buffer solution and a quality control product, wherein the antiserum includes a first phosphate buffer solution and latex particles coupled with a goat anti-human serum amyloid protein A polyclonal antibody; the buffer solution includes a second phosphate buffer solution, sodium chloride and sodium azide; the quality control product includes a solution containing serum amyloid protein A; a mass ratio of the first phosphate buffer solution to the latex particles coupled with the goat anti-human serum amyloid protein A polyclonal antibody is (3-10): 1; and the mass ratio of the second phosphate buffer solution to sodium chloride is 1: (1-2), the mass ratio of the second phosphate buffer solution to sodium azide is (9-12): 1, and a concentration of serum amyloid protein A in the quality control product is 5-300 mg/L. When the kit is used for detecting the content of the serum amyloid protein A, detection time is short, and an operation process is simple.

The invention relates to a set of serum markers for detection of aortic aneurysm/aortic dissection and application thereof. The set of serum markers can be individually used for or arbitrarily combined for distinguishing aortic aneurysm/aortic dissection patients and normal people. The serum markers are protein factors, which include: LCN2: lipocalin, SAA: serum amyloid protein A.

The invention relates to a predication and verification method of a serum amyloid protein A (SAA) antigen epitope and a preparation method of a monoclonal antibody. The predication and verification method comprises the following steps: predicating surface accessibility, an flexibility sequence region, a beta turn, antigenicity, hydrophilicity, a linear epitope and a long-fragment epitope of a serum amyloid protein A antigen to obtain a plurality of epitope sequences respectively; removing repeated epitopes in the plurality of epitope sequences and other sequences contained in other relativelylong epitopes to obtain a plurality of non-redundant predication epitopes; and verifying whether the plurality of non-redundant predication epitopes are identification epitopes of the antibody or notby adopting ELISA (Enzyme Linked Immunosorbent Assay). According to the invention, the problem that the predication accuracy of a single method is low is overcome; through experimental verification, the problem that the SAA antigen epitope is unknown is solved; and the monoclonal antibody is prepared by applying synthesized antigen epitope polypeptide, so that the problem that SAA is difficult topurify and obtain is overcome and the cost is reduced by one time or more.

The invention belongs to the field of clinical medicine detection, and discloses a quality control product of an inflammatory marker and a preparation method of the quality control product. The quality control product of the inflammation marker is composed of a matrix liquid and an inflammation marker component, wherein the matrix liquid is composed of a matrix, a 5-100 mmol/L buffer agent, a 0.01-5 g/L protein protective agent, a 5-100 g/L saccharide and a 0.05-5 g/L preservative; the inflammation marker comprises the following components: procalcitonin, C reactive protein, serum amyloid protein A, myeloperoxidase, interleukin-6 and lipoprotein related phospholipase. The quality control product of the inflammatory marker contains a plurality of inflammatory markers, so that the joint detection of different inflammatory items is realized. Meanwhile, commercial human serum or plasma is adopted as a matrix, the channel source is stable, large-batch production can be achieved, the clinical sample conformity degree is high, the universality is high, the matrix effect can be reduced to the maximum extent, and the uniformity, stability and other performance are good.